Evrysdi Treatment for Spinal Muscular Atrophy

Evrysdi Risdiplam – Spinal Muscular Atrophy Treatment | Complete Clinical Guide

Table of Contents

• What Is Evrysdi?
• How Does It Work?
• Approved Indications
• Dosage & Administration
• Contraindications
• Side Effects
• Monitoring Requirements
• Drug Interactions
• Storage & Handling
• NSL Expert Note
• FAQ

What Is Evrysdi Risdiplam?

Evrysdi risdiplam — the oral risdiplam therapy — is a small-molecule SMN2 splicing modifier — the active treatment in this oral SMA therapy. SMA is caused by mutations in the SMN1 gene, leading to deficiency of survival motor neuron (SMN) protein — essential for motor neuron health. Without adequate SMN protein, motor neurons degenerate, causing progressive muscle weakness and loss of function.

Risdiplam is a systemic treatment that crosses the blood-brain barrier and acts throughout the body, including the central nervous system. Unlike spinal injections (nusinersen/Spinraza) or gene therapy (onasemnogene/Zolgensma), Evrysdi is taken orally at home — a critical advantage for long-term management.

How Does Evrysdi Risdiplam Work?

The SMN2 gene is a backup gene in all SMA patients. Normally, SMN2 produces mostly truncated, non-functional SMN protein due to skipping of exon 7 during splicing. Risdiplam binds to SMN2 pre-mRNA and modifies its splicing — increasing inclusion of exon 7 — so that SMN2 produces more full-length, functional SMN protein. Because risdiplam is orally administered and distributed systemically, it increases SMN protein in both the CNS and peripheral tissues.

Evrysdi Risdiplam – Approved Indications

• SMA Type 1 — infantile-onset, most severe; typically presents within first 6 months
• SMA Type 2 — intermediate; onset 6–18 months
• SMA Type 3 — milder; onset after 18 months, ambulatory patients
• Pre-symptomatic SMA — patients with 1–4 SMN2 copies detected before symptom onset
• Patients from 2 months of age through adulthood

Dosage & Administration

• Infants 2 months to <2 years: weight-based dosing
• Patients ≥2 years and adults: weight-based dosing with maximum caps
• Oral solution (0.75 mg/mL): prepared by pharmacist, administered with calibrated syringe
• Tablets (5 mg): for patients who can swallow tablets

Contraindications

• Known hypersensitivity to risdiplam or any excipient
• Pregnancy — fetotoxic risk confirmed in animal studies; effective contraception required
• Severe hepatic impairment — avoid use

Side Effects

Reproductive toxicity: Women of childbearing potential must use effective contraception during treatment and 1 month after final dose. Male patients: contraception required during treatment and 4 months after final dose.

Monitoring Requirements

• Motor function assessments: CHOP INTEND (infants), HFMSE/RULM (older patients)
• Hepatic function monitoring — especially in patients with pre-existing hepatic conditions
• Ophthalmological monitoring — based on animal study signals
• Regular weight measurements in growing children for dose adjustment
• Nutritional and respiratory monitoring per SMA multidisciplinary care standards

Drug Interactions

Storage & Handling

• Oral solution: refrigerate reconstituted solution (2–8°C); use within 64 days of reconstitution
• Tablets: store below 30°C; protect from moisture
• Use calibrated oral syringe provided; keep out of reach of children

Frequently Asked Questions

What types of SMA does Evrysdi treat?

SMA Types 1, 2, and 3, plus pre-symptomatic SMA in patients from 2 months of age through adulthood.

How is Evrysdi different from Spinraza (nusinersen)?

Spinraza requires intrathecal injection every 4 months in hospital. Evrysdi is taken orally at home once daily — a major practical advantage for long-term management.

Does Evrysdi cure SMA?

No. It is disease-modifying, not curative. It increases SMN protein production, slowing progression and improving motor milestones — but does not restore already-lost motor neurons.

Can Evrysdi be combined with other SMA treatments?

Combination data is limited. The decision to combine treatments must be made by an SMA specialist.

Is Evrysdi safe during pregnancy?

No. Risdiplam is fetotoxic based on animal studies. Effective contraception is required during treatment and 1 month after the final dose.

What if a dose is missed?

Take the missed dose on the same day as soon as remembered. Do not double the dose the following day. Follow prescribing physician guidance.

How long does treatment last?

Evrysdi is an ongoing, long-term treatment. Discontinuation should only be considered under specialist guidance.

What monitoring is required?

Regular motor function assessments, hepatic function monitoring, weight-based dose adjustments as the child grows, and ophthalmological monitoring per specialist recommendation.

Can adults with SMA take Evrysdi?

Yes — Evrysdi is approved from 2 months of age through adulthood, one of the few SMA treatments spanning all age groups.

Where can I obtain Evrysdi in Egypt?

Evrysdi is available through No Style Like as an imported pharmaceutical. Prescription from an SMA specialist is required. Contact us for availability.

Related: Prescription Medicines · Vitamins & Supplements

Reviewed by: Dr. Abdallah Fouad, Clinical Nutrition Specialist — 25+ years of experience

Why Choose Evrysdi risdiplam from No Style Like?

At No Style Like, we provide authentic Evrysdi risdiplam products with verified quality, competitive pricing, and expert guidance from Dr. Abdallah Fouad, Clinical Nutrition Specialist with 25+ years of experience.

Medical Disclaimer: Evrysdi (risdiplam) is a prescription-only medicine for SMA. All treatment decisions must be made by a neurologist experienced in SMA. Educational content only. Source: MedlinePlus – Risdiplam | EMA – Evrysdi